Only 1 out of 3 adults are vaccinated against pertussis1

Despite ACIPa, CDCb, and AAFPc guidelines for Tdapd vaccination,2,3 only 1 in 3 adults received a Tdap vaccine.1

“Persons aged ≥ 19 years who previously have not received a dose of Tdap should receive a single dose of Tdap in place of decennial Tde booster dose.” - ACIP - 20202

    Adacel is indicated for active booster immunization against tetanus, diphtheria, and pertussis. Adacel is approved for use in individuals 10 through 64 years of age.

 

 

 

 

 

Adacel can be given as repeat vaccination and is available in prefilled syringes and vials made without natural rubber latex4

  • Pertussis protection acquired from vaccination can wane.2

initial initialmob
booster boostermob
wound woundmob

After the first and second dose of Adacel, the most frequently reported solicited reactions were pain, swelling, and erythema at the injection site; headache, body ache or muscle weakness, tiredness, myalgia, and malaise.

Other adverse reactions may occur. Vaccination with Adacel may not protect all individuals.

Over 150 Million doses distributed over a decade5

When eligible patients come in
for an Influenza vaccination, also
think Tdap vaccination

 

Help protect your patients as young as 10 years old4

  • Adacel is approved for use in individuals 10 through 64 years of age4
  • You may immunize your adolescent patients as early as the fifth or sixth grade4
  • You may immunize your adolescent patients with Tdap again before they age out of the practice
  • Adacel is available through the VFCg program

 

INDICATION

Adacel is indicated for active booster immunization against tetanus, diphtheria, and pertussis. Adacel is approved for use in individuals 10 through 64 years of age.

IMPORTANT SAFETY INFORMATION

Adacel is contraindicated in persons who have had a severe allergic reaction (e.g., anaphylaxis) to any other tetanus toxoid‐, diphtheria toxoid‐, or pertussis antigen‐containing vaccine, or to any component of Adacel; or encephalopathy within 7 days after a previous dose of a pertussis antigen‐containing vaccine with no other identifiable cause.

If Guillain‐Barré syndrome or brachial neuritis has occurred within 6 weeks following previous vaccination with a tetanus toxoid‐containing vaccine or if progressive or unstable neurologic disorders exist, the decision to give Adacel should be based on careful consideration of the potential benefits and risks.

Persons who experienced an Arthus‐type hypersensitivity reaction following a prior dose of tetanus toxoid‐containing vaccine should not receive Adacel unless at least 10 years have elapsed since the last dose of tetanus toxoid‐containing vaccine.

Syncope can occur in association with administration of injectable vaccines, including Adacel. Procedures should be in place to prevent falling injury and manage syncopal reactions.

After the first and second dose of Adacel, the most frequently reported solicited reactions were pain, swelling, and erythema at the injection site; headache, body ache or muscle weakness, tiredness, myalgia, and malaise.

Other adverse reactions may occur. Vaccination with Adacel may not protect all individuals.

a ACIP = Advisory Committee on Immunization Practices.

b CDC = Centers for Disease Control and Prevention.

c AAFP = American Academy of Family Physicians.

d Tdap = Tetanus, diphtheria, and acellular pertussis.

e Td = Tetanus and diphtheria.

f DTaP = Diphtheria, tetanus toxoids, and acellular pertussis.

g VFC = Vaccines for Children Program.

 

References: 1. CDC. Vaccination coverage among adults in the United States, National Health Interview Survey, 2017. https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2017.html. 2. MMWR Morb Mortal Weekly Rep. 2020 Jan 24;69(3):77-83. 3. American Academy of Family Physicians (AAFP). Adult immunization schedule. https://www.aafp.org/patient-care/public health/immunizations/schedules/adult-schedule.html. Updated February 7, 2018. Accessed November 05, 2020. 4. Adacel vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc. 5. Sanofi Pasteur Inc. Data on File (2019).

*

Back to the top ▲

© 2021 Sanofi Pasteur Inc.

Legal Disclaimer | Privacy Policy | Contact Us

This site is intended for use by US Healthcare Professionals only.

MAT-US-2021577-v2.0-02/2021 Last Updated: February 2021

IMPORTANT SAFETY INFORMATION

Adacel is contraindicated in persons who have had a severe allergic reaction (e.g., anaphylaxis) to any other tetanus toxoid‐, diphtheria toxoid‐, or pertussis antigen‐containing vaccine, or to any component of Adacel; or encephalopathy within 7 days after a previous dose of a pertussis antigen‐containing vaccine with no other identifiable cause.